Ganciclovir clinical trials
Also written Zirgan and Cytovene.
Includes 76 studies of Valganciclovir.
How each study uses Ganciclovir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ganciclovir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Jun 1989 · CYTOVENE · NDA 019661 (FDA, Drugs@FDA)
- European Union
- 18 Mar 1997 · Vitrasert Implant · EMEA/H/C/000120 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
104 studies that test it; most in 2004 (8)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1991 | 1 |
| 1992 | 1 |
| 1994 | 1 |
| 1997 | 2 |
| 1999 | 1 |
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 8 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 103
National Institute of Allergy and Infectious Diseases (NIAID) (23) · Hoffmann-La Roche (22) · University of California, San Francisco (4) · Viracta Therapeutics, Inc. (3) · Fred Hutchinson Cancer Center (3) · Roche Global Development (3) · National Cancer Institute (NCI) (2) · Dr. Ann C.T.M. Vossen (2)
Often tested with
Tested in the same studies.
Foscarnet (5) · Zidovudine (4) · Acyclovir (4) · Bortezomib (3) · Sirolimus (3) · Nanatinostat (3) · Mycophenolic Acid (3) · Prednisone (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Ganciclovir is the comparator. A study of two new drugs counts under both.
- 2Letermovir · Hospital do Rim e Hipertensão, Columbia University · next primary completion Jan 2028
Reaching primary completion within a year · 5
Studies that test Ganciclovir.
- Nov 2026Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsPhase 4 · First Affiliated Hospital Xi'an Jiaotong University
- Feb 2027ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAsePhase 2 · Wits Health Consortium (Pty) Ltd
- May 2027CMV Immunity Monitoring in Lung Transplant RecipientsPhase 2 · NYU Langone Health
- Jun 2027Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus RetinitisEarly Phase 1 · Tianjin Medical University
- Sep 2027A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsPhase 2 · Cecilia Soderberg-Naucler
Studies
Open first, then newest update. How each study uses Ganciclovir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 139
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsRecruitingPhase 3University of California, San FranciscoNCT06798909Written as Valganciclovir (Pre-emptive CMV Therapy)How we know
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and IINot yet recruitingPhase 2University of California, San FranciscoNCT07513623Written as ValganciclovirHow we know
- Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV InfectionRecruitingPhase 2The Methodist Hospital Research InstituteNCT07383649Written as ValganciclovirHow we know
- Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic RhinitisRecruitingNot applicableUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06436534Written as Ganciclovir Oral CapsuleHow we know
- CMV Immunity Monitoring in Lung Transplant RecipientsRecruitingPhase 2NYU Langone HealthNCT05708755Written as ValganciclovirHow we know
- ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAseNot yet recruitingPhase 2Wits Health Consortium (Pty) LtdNCT07379203Written as ValganciclovirHow we know
- Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsRecruitingPhase 4First Affiliated Hospital Xi'an Jiaotong UniversityNCT07266467Written as ValganciclovirHow we know
- Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus RetinitisRecruitingEarly Phase 1Tianjin Medical UniversityNCT05911503Written as 2% Ganciclovir Eye DropsHow we know
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00092222Written as ValganciclovirHow we know
- Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and SepsisTerminatedPhase 3Fred Hutchinson Cancer CenterNCT04706507Written as IV GanciclovirHow we know
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsTerminatedPhase 2Albert ParkNCT03107871Written as ValganciclovirHow we know
- ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSIONCompletedPhase 1/2Laureate Institute for Brain Research, Inc.NCT04724447Written as ValganciclovirHow we know
- Phase 1 Study of GEN2 in Patients With Advanced Solid TumorsTerminatedPhase 1GenVivo, Inc.NCT06391918Written as GEN2 + ValganciclovirHow we know
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment OutcomesTerminatedPhase 2/3University of California, San FranciscoNCT03586284Written as Valganciclovir HydrochlorideHow we know
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsActive, not recruitingPhase 2Cecilia Soderberg-NauclerNCT04116411Written as Valganciclovir TabletsHow we know
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCompletedPhase 2/3Hospital Universitario 12 de OctubreNCT03915366Written as Valganciclovir Oral Solution [Valcyte]How we know
- An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory LymphomasTerminatedPhase 2Viracta Therapeutics, Inc.NCT05011058Written as Nanatinostat in combination with valganciclovirHow we know
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedPhase 1/2Viracta Therapeutics, Inc.NCT03397706Written as VRx-3996 and valganciclovirHow we know
- A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced CancersTerminatedPhase 1Viracta Therapeutics, Inc.NCT06302140Written as Nanatinostat (free base) tablets in combination with ValganciclovirHow we know
- Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic KeratitisCompletedNot applicableAl-Azhar UniversityNCT06757907Written as Ganciclovir (GCV)How we know
See all 139 studies that test Ganciclovir →
Given beside what is tested · 13 — Ganciclovir is usual care or a partner of the new treatment
- Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant RecipientsRecruitingPhase 4University Health Network, TorontoNCT07235683Written as Valganciclovir/GanciclovirHow we know
- Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT06334497Written as ValganciclovirHow we know
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With GlioblastomaRecruitingPhase 1/2Rznomics, Inc.NCT06102525Written as VGCVHow we know
- EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07138989Written as Valganciclovir Hydrochloride TabletsHow we know
- Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV ViremiaNot yet recruitingPhase 2Peking University People's HospitalNCT06971913Written as Ganciclovir (GCV)How we know
- Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCTerminatedPhase 1Viracta Therapeutics, Inc.NCT05166577Written as ValganciclovirHow we know
- Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedPhase 2National Cancer Institute (NCI)NCT01441063Written as Valganciclovir (VGC)How we know
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver TransplantationTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02188719Written as Anti-Infective ProphylaxisHow we know
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus InfectionCompletedPhase 4Medical University of South CarolinaNCT01509404Written as ValganciclovirHow we know
- Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex KeratitisStatus unknownNot applicableChunxiao WangNCT03217474Written as Ganciclovir (GCV)How we know
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) TransplantationCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00141037Written as GanciclovirHow we know
- Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 2Huazhong University of Science and TechnologyNCT02202564Written as ganciclovirHow we know
- Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative DisordersTerminatedPhase 2HemaQuest Pharmaceuticals Inc.NCT00992732Written as Valganciclovir (may substitute with ganciclovir)How we know
As the comparator · 12 — what is tested is compared with Ganciclovir
- Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingPhase 2/3Columbia UniversityNCT07079735Written as ValganciclovirHow we know
- Study Evaluating the Efficacy and Safety of ArtesunateRecruitingPhase 2Amivas Inc.NCT06853184Written as Ganciclovir (GCV)How we know
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNot applicableNational Taiwan University HospitalNCT07294547Written as Valganciclovir (Valcyte)How we know
- Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus InfectionNot yet recruitingPhase 3Hospital do Rim e HipertensãoNCT06341686Written as GanciclovirHow we know
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant RecipientsCompletedPhase 4Medical University of South CarolinaNCT06034925Written as ValganciclovirHow we know
- Letermovir for CMV Prevention After Lung TransplantationCompletedPhase 2Fernanda P Silveira, MD, MSNCT05041426Written as ValganciclovirHow we know
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)CompletedPhase 3Merck Sharp & Dohme LLCNCT03443869Written as ValganciclovirHow we know
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedPhase 3ShireNCT02927067Written as ValganciclovirHow we know
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney TransplantationCompletedPhase 2University of MinnesotaNCT01972035Written as ValganciclovirHow we know
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedPhase 3ShireNCT02931539Written as GanciclovirHow we know
- Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant RecipientsCompletedPhase 3ShireNCT00497796Written as ganciclovirHow we know
- Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)CompletedPhase 3Johns Hopkins Bloomberg School of Public HealthNCT00000134Written as GanciclovirHow we know
Codes
What other systems call Ganciclovir · ClinicalTrials.gg INT008500
- MeSH (NLM) D015774GanciclovirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P9G3CKZ4P5GANCICLOVIRConfirmed FDA, NLM, Wikidata
- RxNorm 4678Confirmed FDA, Wikidata
- Wikidata Q417640ganciclovirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C517GanciclovirOne source FDA
- DrugBank DB01004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015774 | Ganciclovir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P9G3CKZ4P5 | GANCICLOVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 4678 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417640 | ganciclovir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C517 | Ganciclovir | One source FDA |
| DrugBank | DB01004 | — | One source Wikidata |
Also registered as ganciclovir sodium (UNII 02L083W284 · RxNorm 82131).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.